To provide the information your oncologist is not telling you or doesn't have the time to!
Explore the world of melanoma, a formidable form of skin cancer, through our dedicated “Melanoma” subcategory. Gain valuable insights into the causes, risk factors, and early detection of melanoma. Dive deep into the latest advancements in melanoma treatment options, including surgical interventions, immunotherapy, and targeted therapies. Whether you’re seeking information for prevention, diagnosis, or support, this subcategory is your trusted resource for comprehensive knowledge about melanoma. Together, we’ll navigate this journey toward melanoma awareness and effective management.
Three-year NADINA data showed something that shouldn’t happen: near-complete responders did substantially worse than partial responders — 62.3% versus 87.5% recurrence-free survival. One design feature separates NADINA from every neoadjuvant melanoma trial before it. NADINA mandated full lymph node dissection in every patient; PRADO left the basin alone in major responders. I think that may be the explanation, and nobody raised it.
Four randomized trials and one excellent symposium defined day one of the melanoma program at ESMO 2026 in Madrid: an oral HDAC inhibitor added to nivolumab, a BRAF/MEK-plus-immunotherapy triplet, two trials pushing TIL cell therapy earlier and lighter, and a landscape in metastatic uveal melanoma that has changed faster than most providers realize. Here is the data as presented, and my take on each.
After two rejections, the FDA approved a new melanoma therapy that finally reaches beyond the skin — into the liver, into the lungs. Here’s why the third try worked.
The BRAF Pathway to TIL Program transforms TIL therapy from a last-minute scramble into a proactive treatment strategy.
When science stays the course, time becomes part of the treatment.
Protecting vision, preserving the person — the promise of ocular-sparing oncology.
When innovation meets immune activation, new possibilities emerge for melanoma care.
Targeting PRAME with TCR-T cell therapy may mark a new era for immunotherapy in melanoma and beyond.
From early-stage to brain metastases, ASCO’s latest melanoma abstracts spotlight the growing power of targeted and immune-based therapies across disease stages.
ctDNA is helping us track what truly matters—real-time, personalized signals that guide smarter decisions in cancer care.